One commercial pharmacogenomic panel was linked to modest gains in antidepressant response

Design

Systematic review and meta-analysis of randomised trials (platform-specific primary analysis)

Population

Eight trials in adults with major depressive disorder; three used the single panel in the primary analysis

Primary outcome

Response and remission at 8 to 12 weeks

Effect

Single panel: response RR 1.30 (95% CI 1.09 to 1.56), remission RR 1.53 (95% CI 1.19 to 1.97); other panels: response RR 1.18 (95% CI 0.91 to 1.54)

This meta-analysis, published on 10 July 2026, included eight randomised trials of pharmacogenomic-guided antidepressant prescribing against usual care in adults with major depression, searched to April 2026. It analysed one commercial combinatorial panel on its own and pooled the other multigene panels separately.

For the single panel (three trials), guided care increased response (RR 1.30, 95% CI 1.09 to 1.56; I2 = 0%) and remission (RR 1.53, 95% CI 1.19 to 1.97; I2 = 0%) within 8 to 12 weeks. For the other panels (five trials for response, four for remission) the effects were heterogeneous and imprecise: response RR 1.18 (0.91 to 1.54; I2 = 78%) and remission RR 1.18 (0.77 to 1.80; I2 = 82%).

The trials were short and few, with residual risk-of-bias concerns, and the authors caution against reading the result as one platform being superior. For prescribers, the evidence is modest and platform-specific. It does not support routine testing of every patient with depression.

• For one commercial panel in three trials, response RR was 1.30 and remission RR 1.53 at 8 to 12 weeks.
• Across other multigene panels, results were heterogeneous (I2 about 80%) and imprecise.
• The trials were short, so longer-term benefit is not established.
• Testing does not replace clinical review of interacting drugs and adherence.
• The authors state the analysis does not show one platform is better than others.

Why it matters

It suggests that pooling all pharmacogenomic panels hides a platform-specific effect, and that the benefit is modest even where it is present.

Don't overread it

The evidence comes from a small number of short trials, and the analysis does not establish superiority of any commercial platform.

The statistics, in plain English

An I2 of 0% means the three trials agreed closely, while 78% to 82% means the other trials disagreed substantially, so a single pooled number for those panels would mislead. A risk ratio of 1.30 means about 30% more people responded with guided care.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.